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METHODS: Special clinical methods were used for health
condition evaluation. Our first research of some of the
QoL factors was held in 1996–97.
RESULTS: It was conducted on 561 patients with differ-
ent oncological diseases, including retroperitoneal malig-
nant diseases. The period of remission for 59% of the pa-
tients was 5–10 years, for the rest 41%—5 years. Ages of
the patients varied from 3–7 years to 15 years and over.
Their physical condition was studied (including cardiovas-
cular, urinary, immunological, reproductive, muscular and
other systems), as well as their psychological condition
and social adaptation.
CONCLUSIONS: Only 40% of the patients don’t have
significant after-effect from their anti-tumor therapy. Dys-
function of the immune system was found in 78% of the
examined patients, of the alimentary canal, 67%, of the
central nervous system, 60%, of the muscle and bone and
the urinary tract systems, 56% and 50% respectively. To-
gether with psychological and social problems this consid-
erably influences the QoL of such patients. The research
was continued by the evaluation of life conditions of 278
patients cured from malignant retroperitoneal tumors, as
well as by the analysis of the obtained data in accordance
with the international life-level standards. For this purpose
we are currently adopting the selected interrogatory sheets
EQ-50 (for adult patients) and SP-36 for children. The re-
sults will be introduced in future publications.
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The Israeli National Health Insurance Law enacted in
1995 determines a list of health services including a list of
reimbursed drugs (NLRD). Accordingly, each citizen is
entitled to receive health services of established quality
within the framework of the available resources. In the
last decade, significant advances in R&D have resulted in
the emergence of numerous expensive drugs in the phar-
maceutical market. Hence, the Pharmacoeconomics Unit
at the Pharmaceutical Administration of the Ministry of
Health established a mechanism for updating the NLRD,
based on the evaluation of clinical, epidemiological and
economic data. Prior to the presentation of guidelines for
the pharmaceutical industry on submission of economic
data as part of a request for the inclusion of a pharma-
ceutical product in the NLRD, a survey was conducted to
examine existing pharmacoeconomic knowledge of the
Israeli pharmaceutical industry. The results of the survey
indicated that the pharmaceutical industry has very little
pharmacoeconomic knowledge. These results prompted a
lenient approach to the submission of requests for the
next two years during which the industry is expected to
develop a firm pharmacoeconomic basis. Guidelines on
submission of a request to include a pharmaceutical
product in the NLRD were presented to the pharmaceuti-
cal industry. The dossier to be submitted by the industry
consists of three sections:
Clinical—treatment regimens, adverse effects, effi-
cacy and safety in comparison to alternate therapies.
Epidemiological—morbidity figures, definition of tar-
get population, sales figures.
Economic—cost of the suggested treatment compared
to that of alternative therapies and an economic evalu-
ation.
260 different requests have been submitted for the 2000
update of the NLRD, according to the guidelines, and are
currently being processed. Following the 2000 update, a
reassessment will take place, and the guidelines will be
changed according to the experience incurred by both the
industry and the Ministry of Health.
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OBJECTIVES: To survey expert opinion on trends in
economic evaluation by UK pharmaceutical and medical
device firms, from R&D to product launch and beyond.
The background is the move in some EU countries, exem-
plified by NICE in UK, towards emulating the Australian
“fourth hurdle” of mandatory economic data require-
ments before pharmaceutical purchasing.
METHODS: Interviews with a range of experts from UK
industry and academia. Industry representatives included
both science experts and policy experts from six pharma-
ceutical firms and four medical device firms; academics
included both health economists and pharmaceutical pol-
icy specialists.
RESULTS: Dramatic increase over the last decade in pro-
duction of pharmacoeconomic evidence at late develop-
ment and early marketing stages in response to more ag-
gressive management of pharmaceutical budgets. Medical
device firms lag behind, due to smaller size and less aggres-
sive purchasers, but large firms are now starting to design
trials with economic evaluation in mind. Limited improve-
ment in scientific quality of pharmacoeconomic evidence
in relation to state-of-the-art methodology (“Washington
Guidelines”); limited use of effectiveness trials, utility indi-
ces, cost-utility analysis, sensitivity analysis. Limited use of
prospective cost-effectiveness modeling in R&D go/no go
decisions, even though prospective modelling of return
on investment is routinely used from early development
onwards. Some industry representatives argue that phar-
macoeconomics cannot be used to prioritize R&D since
“hard” data are not available and uncertainties are great.
